Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.79 USD | -0.26% | -12.96% | +26.87% |
May. 15 | Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 01 | Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label | MT |
Evolution of the average Target Price on Solid Biosciences Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Solid Biosciences Inc.
William Blair & Co. | |
Barclays | |
Citigroup | |
Piper Sandler | |
HC Wainwright | |
Cantor Fitzgerald | |
SVB Securities LLC | |
JPMorgan Chase | |
Chardan Research | |
SVB Leerink | |
Chardan | |
Jefferies & Co. | |
Credit Suisse | |
Evercore ISI |
EPS Revisions
- Stock Market
- Equities
- SLDB Stock
- Consensus Solid Biosciences Inc.